ORIC Pharmaceuticals Inc (ORIC)
13.73
+0.27
(+2.01%)
USD |
NASDAQ |
Mar 28, 16:00
13.73
0.00 (0.00%)
After-Hours: 20:00
ORIC Pharmaceuticals Cash from Financing (TTM): 85.66M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 85.66M |
September 30, 2023 | 110.00M |
June 30, 2023 | 109.97M |
March 31, 2023 | 25.21M |
December 31, 2022 | 25.22M |
September 30, 2022 | 1.245M |
June 30, 2022 | 49.83M |
March 31, 2022 | 49.13M |
December 31, 2021 | 49.13M |
Date | Value |
---|---|
September 30, 2021 | 173.82M |
June 30, 2021 | 124.89M |
March 31, 2021 | 252.16M |
December 31, 2020 | 250.51M |
September 30, 2020 | 124.96M |
June 30, 2020 | 131.00M |
March 31, 2020 | 53.93M |
December 31, 2019 | 70.82M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.245M
Minimum
Sep 2022
252.16M
Maximum
Mar 2021
99.26M
Average
85.66M
Median
Dec 2023
Cash from Financing (TTM) Benchmarks
Geron Corp | 362.02M |
Verastem Inc | 134.19M |
Karyopharm Therapeutics Inc | 1.124M |
Blueprint Medicines Corp | 119.22M |
Syndax Pharmaceuticals Inc | 264.13M |